US judge rules Merck won't face "punitive damages" in first Fosamax case.

Ray Moynihan

doi:10.1136/bmj.b3225

US judge rules Merck won't face "punitive damages" in first Fosamax case.

Ray Moynihan^*

^*Corresponding author for this work

Institute for Evidence-Based Healthcare

Research output: Contribution to journal › Comment/debate/opinion › Professional

Abstract

A district court judge in the United States has ruled that the drug maker Merck will not face the risk of “punitive damages” in the first case to be tried involving its widely prescribed osteoporosis drug, Fosamax (alendronate or alendronic acid).

Original language	English
Pages (from-to)	b3225-b3225
Number of pages	1
Journal	BMJ (Clinical research ed.)
Volume	339
DOIs	https://doi.org/10.1136/bmj.b3225
Publication status	Published - 2009

Access to Document

10.1136/bmj.b3225

Cite this

@article{01bee78deec94722941858635f6a1e00,

title = "US judge rules Merck won't face {"}punitive damages{"} in first Fosamax case.",

abstract = "A district court judge in the United States has ruled that the drug maker Merck will not face the risk of “punitive damages” in the first case to be tried involving its widely prescribed osteoporosis drug, Fosamax (alendronate or alendronic acid).",

author = "Ray Moynihan",

year = "2009",

doi = "10.1136/bmj.b3225",

language = "English",

volume = "339",

pages = "b3225--b3225",

journal = "BMJ (Clinical research ed.)",

issn = "0959-535X",

publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - US judge rules Merck won't face "punitive damages" in first Fosamax case.

AU - Moynihan, Ray

PY - 2009

Y1 - 2009

N2 - A district court judge in the United States has ruled that the drug maker Merck will not face the risk of “punitive damages” in the first case to be tried involving its widely prescribed osteoporosis drug, Fosamax (alendronate or alendronic acid).

AB - A district court judge in the United States has ruled that the drug maker Merck will not face the risk of “punitive damages” in the first case to be tried involving its widely prescribed osteoporosis drug, Fosamax (alendronate or alendronic acid).

UR - https://www.scopus.com/pages/publications/68849106548

U2 - 10.1136/bmj.b3225

DO - 10.1136/bmj.b3225

M3 - Comment/debate/opinion

C2 - 19661146

AN - SCOPUS:68849106548

SN - 0959-535X

VL - 339

SP - b3225-b3225

JO - BMJ (Clinical research ed.)

JF - BMJ (Clinical research ed.)

ER -

US judge rules Merck won't face "punitive damages" in first Fosamax case.

Abstract

Access to Document

Other files and links

Fingerprint

Cite this